{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"10","upperLimit":"57","value":"33"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"15"}],"units":"Participants"}],"description":"Measured by AGVHD Grades 2 - 4.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receiving study regimen.\n\nStem Cell Transplant: Transplantation on Day 0.\n\nPreparative Regimen: - Busulfan\n\n* Cyclophosphamide\n* Mesna\n* Melphalan\n* Anti-thymocyte Globulin (ATG)","id":"OG000","title":"Intent-to-Treat"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"at 1 year after transplant","title":"Combined Incidence of Neutrophil Engraftment, Graft-versus-host Disease (GVHD), Regimen-related Toxicity, and Relapse.","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}